FCGRT and neoplasm: Since Aza increases the expression of FcRn in model cell lines, it will be of interest to evaluate whether Aza treatment modifies a) the pharmacological behavior (e.g., pharmacokinetics) of Fc-containing monoclonal antibody drugs, and b) albumin tumor consumption in the context of therapy for AML/MDS33,34.